Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Fecal Hemoglobin Stability Evaluated for FITs

By LabMedica International staff writers
Posted on 31 Oct 2017
Screening with guaiac-based fecal occult blood tests (gFOBT), followed by colonoscopy for patients who test positive, has been associated with a reduction of 15% to 33% in colorectal cancer (CRC)–related mortality.

Fecal immunochemical test (FIT) methods have been developed. More...
These immunoassays form an antibody antigen complex with the globin moiety of human hemoglobin (Hb) to generate either an immunoturbidimetric signal, which can be measured quantitatively or by lateral-flow immunochromatographic analysis, a qualitative band that can be detected visually.

A large team of scientists collaborating with those at Sunnybrook Research Institute (Toronto, ON, Canada) implemented a novel, standardized method to compare Hb stability across various fecal immunochemical tests. The stability of Hb was analyzed in collection devices inoculated with Hb-spiked feces and (1) stored at various temperatures (frozen, refrigerated, ambient, and elevated) for more than 60 days; (2) after undergoing three controlled, freeze-thaw cycles; and (3) after being transported by courier or postal services in uncontrolled temperature conditions from three locations in Ontario, Canada, to a central testing center. The team compared the stability of Hb across five different immunochemical kits and one guaiac kit.

The scientists found that the stability of Hb varied with time and temperature and by kit. Lower Hb recoveries occurred with increasing temperature and increasing time from sample collection to testing. Refrigeration provided the best stability, although results varied across kits, from 4.2 days to more than 60 days before a pre-specified threshold with less than 70% probability of the test results remaining positive was reached.

Freeze-thaw stability varied across kits and cycles. Hb recoveries from Hemoglobin NS-Plus, was 91.7% to 95.4%; while for OC-Sensor Diana, the Hb recovery was 57.6% to 74.9%. Agreement regarding Hb levels before and after transportation varied across kits, from 57% to 100%. The scientists found that the Hema-Screen SPECIFIC, was the best performer among the qualitative kits.

The authors concluded that important differences in Hb stability were found across the included fecal immunochemical tests and these findings should inform practice-based and population-based colorectal cancer screening. The study was published on October 2, 2017, in the journal Archives Of Pathology & Laboratory Medicine.

Related Links:
Sunnybrook Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.